8-K - Allarity Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Allarity Therapeutics, Inc. announced on February 18, 2026 that the first patients have been dosed with stenoparib and temozolomide. The announcement is disclosed under Item 8.01 with a related press release in Exhibit 99.1.

Key Takeaways

1First patients dosed with stenoparib and temozolomide on or before February 18, 2026.

2Announcement dated February 18, 2026.

3Press release furnished as Exhibit 99.1.

4Filing dated February 19, 2026.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Matters. On February 18, 2026, Allarity Therapeutics, Inc. (the “Company”) announced that the first patients have been dosed with stenoparib and temozolom

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated February 18, 2026. 104 Cover Page Interactive Data File (e

Exhibits Only

Source Document

Exhibits (2)

8-K

CURRENT REPORT

99.1

PRESS RELEASE, DATED FEBRUARY 18, 2026